Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -92.06% | -87.40% | -106.46% | -116.28% | 6.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.06% | -87.40% | -106.46% | -116.28% | 6.04% |
| Cost of Revenue | -84.19% | -94.77% | -53.41% | -22.75% | 105.87% |
| Gross Profit | 75.48% | 104.30% | -392.50% | -1,349.87% | -4,953.73% |
| SG&A Expenses | 47.49% | -35.22% | -36.16% | -33.13% | -15.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.17% | -75.62% | -44.26% | -28.49% | 50.99% |
| Operating Income | 24.63% | 68.32% | -0.77% | -52.63% | -108.34% |
| Income Before Tax | 26.12% | 61.73% | 9.24% | -38.40% | -80.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.12% | 61.73% | 9.24% | -38.40% | -80.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.12% | 61.73% | 9.24% | -38.40% | -80.81% |
| EBIT | 24.63% | 68.32% | -0.77% | -52.63% | -108.34% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.38% | 63.79% | 10.26% | -37.55% | -80.17% |
| Normalized Basic EPS | 29.50% | 63.10% | 9.52% | -37.11% | -78.77% |
| EPS Diluted | 30.38% | 63.79% | 10.26% | -37.55% | -80.17% |
| Normalized Diluted EPS | 29.50% | 63.10% | 9.52% | -37.11% | -78.77% |
| Average Basic Shares Outstanding | 4.76% | 5.34% | 2.68% | 1.46% | 0.65% |
| Average Diluted Shares Outstanding | 4.76% | 5.34% | 2.68% | 1.46% | 0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |